News Summaries

China’s Biotech Boom: Sales Rise, New Oral Weight‑Loss Pill Approved, and Companies Eye Global Deals

Half‑year data shows China’s biopharma sector is finally turning a profit. Revenue from 362 listed companies hit 889.9 billion yuan in the first six months, a 2.8 % year‑on‑year increase, while operating profit jumped 11.2 % to 113.7 billion yuan. The era of chronic losses and heavy reliance on financing is ending as domestic innovators focus on profitability, overseas expansion and more efficient R&D. A headline win came when Novo Nordisk’s oral version of Wegovy (semaglutide) received formal acceptance from China’s drug regulator. The pill will make GLP‑1 weight‑loss therapy far more accessible, shifting the market away from injections toward convenient tablets. Beyond GLP‑1, Chinese firms are racing to launch multi‑target, long‑acting and oral peptide drugs, extending product pipelines and lengthening commercialization timelines. Internationally, China’s innovative‑drug deals surged 34.5 % in the first half of 2026, with overseas transactions now accounting for more than 30 % of total value. Investors are gravitating toward low‑risk, high‑growth opportunities. Analysts highlight the Hang Seng Stock Connect Innovative Drug ETF (159570) – a 100 % innovative‑drug fund – as a way to capture the sector’s upside while de‑risking exposure. The overall picture is one of a maturing, globally‑connected biotech industry poised for continued expansion.

Three Hot IPO Picks: AI Chip Pioneer, Peptide Drug Maker, and Innovative Cancer Drug Firm

Three Chinese companies are drawing investor buzz this year, each carving out a niche in fast‑growing health‑tech and AI markets. First, Baimaike, a high‑tech medical‑device maker, broke foreign monopolies by launching China’s first absorbable knot‑less sutures, now holding the biggest domestic share (about 9%) in a market still dominated by imports. Its sister unit, Hainan Jianbang, built a fully automated peptide‑synthesizer that lets Chinese drug makers scale up peptide medicines. In 2023‑25 the firm generated roughly 180‑215 million RMB in revenue and earned around 70 million RMB in profit each year, though margins slipped as suture prices fell. Second, Suiyuan Technology, founded in 2018, is a home‑grown cloud AI‑chip champion. It has rolled out five AI chips and sells acceleration cards that captured roughly 1.7% of China’s AI‑card market in 2025—enough to rank it among the top domestic players. Revenue surged from 301 million RMB in 2023 to nearly 1 billion RMB in 2025, but heavy R&D spending left it loss‑making, with a net loss of about 1.2 billion RMB. The company hopes to turn profitable by 2026‑27, though most of its sales (over 80%) come from a single partner, Tencent. Third, Sinovant Sciences, a 2017‑born biotech, is pushing a “1+3+N” drug pipeline that includes one NDA under review, three late‑stage trials, and numerous early projects across cancer and infections. It ranks fourth among STAR Market firms for China’s Breakthrough‑Therapy designations and is also a top contender for U.S. FDA Fast‑Track status. The firm plans to issue new shares worth 15% of its post‑offering capital, aiming to fund its ambitious pipeline. Together, these three firms illustrate how Chinese innovators are challenging global leaders in medical devices, peptide manufacturing, AI hardware, and breakthrough medicines, offering investors a mix of high‑growth potential and early‑stage risk.

Breakthrough CAR‑T Therapies Show Hope: Long‑Term Survival Boost for Aggressive Lymphoma and 80% Remission Spike in Childhood Neuroblastoma

A new generation of CAR‑T cell immunotherapy is delivering life‑changing results for two of the toughest cancers. In a five‑year follow‑up of a large trial published in *Blood*, the drug lisocabtagene maraleucel (liso‑cel) helped patients with relapsed or refractory large B‑cell lymphoma live much longer. Out of 257 participants, the median overall survival jumped to 27.5 months, and 38 % were still alive after five years. When deaths unrelated to lymphoma were excluded, the median disease‑specific survival stretched to nearly 68 months, with a 52 % five‑year survival rate. For those who responded well enough to enter long‑term monitoring, the numbers were even more striking—78 % survived five years and 92 % remained disease‑free. In a separate pre‑clinical study reported in *Cell Reports Medicine*, researchers at the University of Pittsburgh and the National Cancer Institute combined CAR‑T cells with a targeted radiopharmaceutical to treat neuroblastoma, a rare childhood tumor that grows in nerve tissue. The combo therapy shrank tumors dramatically, boosting complete remission rates by about 80 % compared with radiation alone. The findings suggest that pairing CAR‑T cells with precise radiation could become a powerful new weapon against aggressive cancers, offering renewed hope for patients and families facing limited options.